Upsher-Smith Laboratories, Inc. v. Federal Insurance

264 F. Supp. 2d 843, 2002 U.S. Dist. LEXIS 26382, 2002 WL 32100695
CourtDistrict Court, D. Minnesota
DecidedAugust 29, 2002
DocketCIV. 01-1573 (DSD/SRN)
StatusPublished
Cited by5 cases

This text of 264 F. Supp. 2d 843 (Upsher-Smith Laboratories, Inc. v. Federal Insurance) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Upsher-Smith Laboratories, Inc. v. Federal Insurance, 264 F. Supp. 2d 843, 2002 U.S. Dist. LEXIS 26382, 2002 WL 32100695 (mnd 2002).

Opinion

ORDER

DOTY, District Judge.

This matter is before the court on the cross-motions of the parties for summary judgment. For the following reasons, the court will grant defendant’s motion for summary judgment [Doc. No. 24] and deny plaintiffs motion for summary judgment [Doc. No. 26]. 1

BACKGROUND

This case involves an insurance coverage action. Plaintiff is seeking a declaration of the duty to defend under defendant Federal Insurance Company’s (“Federal”) Insurance Policy No. 7948-49-36 (“the policy”), which included an Insured Organization Coverage Endorsement set forth in Federal Endorsement Form 14-02-2287, for a complaint filed by the Federal Trade Commission (“FTC”) and more than forty private civil litigation actions. Defendant contends that since there is an exclusion in the policy directly excluding coverage, it has no duty to defend plaintiff.

A. The Underlying FTC Proceeding

Upsher-Smith Laboratories Inc. (“Upsher-Smith”) is a Twin Cities based pharmaceutical company that develops and manufactures a wide range of products. In the mid 1990s, Upsher-Smith developed a generic alternative to a well-known potassium supplement which was sold by Schering-Plough Corporation (“Scher-ing”). During the regulatory review process of Upsher-Smith’s generic alternative, Schering commenced a lawsuit in New Jersey alleging that the formulation of Upsher-Smith’s product infringed upon a patent that Schering held. After many years of litigation, the parties settled the patent infringement action in a manner that allowed Upsher-Smith to obtain final FDA approval for its potassium supplement and to release that product for sale more than five years before the expiration of the Schering patent (the “settlement agreement”).

The FTC conducted an investigation of the settlement agreement, and in March *845 2001, commenced an administrative proceeding attacking the settlement agreement. On March 30, 2001, the FTC filed a complaint naming Upsher-Smith and Schering as respondents. (See Klimczyk Aff. Ex. C.) The FTC complaint alleged that respondents had engaged in conduct that violated Section 5 of the FTC Act. 2 (Id.) The FTC complaint sought various forms of equitable relief, including an order that each respondent “cease and desist” from activity in violation of the Section 5 of the FTC Act. (Id.) According to plaintiff, the FTC’s claim arose from a complex interplay between certain market exclusivity provisions for first-time filers, like Upsher-Smith, conferred by the regulatory authority of the Food and Drug Administration (“FDA”) to approve new generic drugs and the FTC’s authority to regulate competition. (Pl.’s Mem. at 3.)

B. The Private Civil Actions

During the seven-month period following the filing of the FTC complaint, more than forty private civil actions were filed against Upsher-Smith in state and federal courts throughout the country (the “private civil actions”). Each private civil action complaint referenced the FTC proceeding, recited nearly identical factual allegations against Upsher-Smith, and included causes of action for restraint of trade, deceptive trade practices or various antitrust violations under the applicable federal or state antitrust authority. (See Klymczyk Aff. ¶¶ 5-46, Exs. D-SS.) 3 As described by Upsher-Smith, “... each complaint [was] based on the same set of operative facts that underlies the FTC complaint ...” (Comply 24.) Many of these complaints repeat verbatim many of the allegations contained in the FTC complaint.

Furthermore, each of the complaints was brought either on behalf of a defined class of consumers, for example, “end users” or “end payors,” or by direct purchasers, for example, drugstores or retail pharmacies. In addition to Upsher-Smith, these actions also named as defendants Schering and others. In addition to requests for injunctive relief, these complaints also seek relief in the form of common law causes of action including restitution, unjust enrichment, and disgorgement. 4 Many of these cases were *846 removed to, and eventually consolidated in, the United States District Court for the District of New Jersey (the “MDL proceeding”). 5

C. The Insurance Policy

Federal issued the first of several claims-made insurance policies to Upsher-Smith with the initial policy, Policy No. 7948-49-36, covering the period April 17, 1998 to April 17, 1999. Upsher-Smith renewed the policy for the period of April 17, 1999 to April 17, 2000, and again for the period April 17, 2000 to April 17, 2001, Policy No. 7948-49-36B. The policy included a $5,000,000 limit of liability. The policy further contains five separate insuring clauses. The parties agree that only insuring clause 5, entitled “Insured Organization Coverage,” could potentially afford coverage for the underlying litigation against Upsher-Smith.

Insuring clause 5 states as follows:

Insured Organization Coverage

The Company shall pay on behalf of any Insured Organization all Loss for which it becomes legally obligated to pay on account of any Claim first made against the Insured Organization during the Policy Period or, if exercised, during the Extended Reporting Period, for a Wrongful Act committed, attempted, or allegedly committed or attempted, by any Insured before or during the Policy Period.

(Johnston Aff. Ex. A.)

Section 16 of the policy sets forth Federal’s duty to defend, providing:

The Company shall have the right and duty to defend any Claim covered by this Policy. Coverage shall apply even if any of the allegations are groundless, false or fraudulent. The Company’s Duty to Defend shall cease upon exhaustion of the Company’s applicable Limit *847 of Liability set forth in Item 4 of the Declarations.

(Id.)

A claim under clause 5 is defined as:

(a)a •written demand for monetary damages, (b) a civil proceeding commenced by the service of a complaint or a similar pleading, or (c) a criminal proceeding commenced by a return of an indictment, against an Insured Organization for a Wrongful Act, including any appeal therefrom.

The policy defines ‘Wrongful Act” as “any error, misstatement, misleading statement, act, omission, neglect or breach of duty committed, attempted, or allegedly committed or attempted by ... any Insured Organization.” (Id.)

The Limits of Liability section of the Policy provides:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
264 F. Supp. 2d 843, 2002 U.S. Dist. LEXIS 26382, 2002 WL 32100695, Counsel Stack Legal Research, https://law.counselstack.com/opinion/upsher-smith-laboratories-inc-v-federal-insurance-mnd-2002.